Lv3
254 积分 2025-05-14 加入
Abstract 1697: CPI-169, a novel and potent EZH2 inhibitor, synergizes with CHOP in vivo and achieves complete regression in lymphoma xenograft models
13天前
已完结
Recent advances in EZH2-based dual inhibitors in the treatment of cancers
14天前
已完结
Triflylpyridinium Enables Rapid and Scalable Controlled Reduction of Carboxylic Acids to Aldehydes using Pinacolborane
15天前
已完结
TheStille Reaction
15天前
已完结
A pharmacological modality to sequester homomeric proteins
17天前
已完结
Development of Dual and Selective Degraders of Cyclin‐Dependent Kinases 4 and 6
17天前
已完结
Recent update on the development of EZH2 inhibitors and degraders for cancer therapy
18天前
已完结
Therapeutic horizons in the development of PROTAC-based EZH2 inhibitors: recent achievements, comparative analysis, and future perspectives
18天前
已完结
An Overview on Small Molecule Inhibitors of BRD4
19天前
已完结
Novel Dihydropteridinone Derivatives As Potent Inhibitors of the Understudied Human Kinases Vaccinia-Related Kinase 1 and Casein Kinase 1δ/ε
20天前
已完结
皖公网安备34019202002308
